Evidence map›Paper›PMID 39660157›Full record

ArticleLe infezioni in medicina2024

Single dose ivermectin for scabies pre-emptive therapy among healthcare workers in Careggi University Hospital, Florence, Italy.

Riccardo Paggi, Marco Pozzi, Beatrice Borchi, Elisabetta Mantengoli, Giulia Bandini, Alessandra Ipponi, Annarita Chiarelli, Diana Paolini, Michele Cecchi, Giulio Arcangeli and 4 more

Abstract read
In one paragraph

Article in Le infezioni in medicina, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Riccardo PaggiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Marco PozziInfectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
Beatrice BorchiInfectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
Elisabetta MantengoliInfectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
Giulia BandiniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Alessandra IpponiHospital Pharmacy and Pharmaceutical Policies, Careggi University Hospital, Florence, Italy.
Annarita ChiarelliOccupational Medicine Unit, Careggi University Hospital, Florence, Italy.
Diana PaoliniHospital Health Management, Careggi University Hospital, Florence, Italy.
Michele CecchiPharmacy AD Preparation Unit, Careggi University Hospital, Florence, Italy.
Giulio ArcangeliDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Fabrizio NiccoliniHospital Health Management, Careggi University Hospital, Florence, Italy.
Alberto Moggi PignoneDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Alessandro BartoloniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Lorenzo ZammarchiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Scabies is a neglected disease that cause outbreaks in facilities such as hospitals and prisons. In Europe, treatment with 2 doses of ivermectin 200 mcg/kg, 7 days apart, is authorised and recommended especially in population mass treatment. We describe the management of a mass pre-emptive therapy of primary contacts of a confirmed case of classic scabies among health care workers. Patients and Methods: Hospital personnel were evaluated, and at-risk contacts were treated with oral ivermectin 200 mcg/kg single dose if asymptomatic. Hospital staff were called after 7, 30, and 60 days after the first visit to assess presence of adverse drug reactions (ADRs) or symptoms compatible with scabies. Results: Among 27 patients evaluated, 19/27 (70.4%) received single dose ivermectin for scabies pre-emptive therapy. A total of 11/13 patients were nurses, and 8/14 were healthcare assistants. A total of 87 tablets of ivermectin were administered, with a total cost of 423.69 euros. Two people reported ADRs at 7 days; one and two patients reported possible ADRs at 30 and 60 days, respectively. The efficacy in preventing scabies was 100%. Discussion and conclusions: To our knowledge, this is the first Italian experience in which a single dose of ivermectin has been implemented for mass pre-emptive therapy in asymptomatic primary contacts of classical scabies, showing excellent efficacy of the drug even when used as a single dose.

Indexed as

in-hospital outbreakivermectinpre-emptive treatmentscabies

Identifiers

PMID39660157
PMCPMC11627492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.